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Abstract
Objective: The aim of this study was to analyze brain pathologies which cause
dementia in the oldest old population. Methods: All 601 persons aged
≥85 years living in the city of Vantaa (Finland), on April 1st, 1991 formed the
study population of the Vantaa85 + study, 300 of whom were autopsied dur-
ing follow-up (79.5% females, mean age-at-death 92  3.7 years). Alzheimer’s
disease (AD) pathology (tau and beta-amyloid [Ab]), cerebral amyloid angiopa-
thy (CAA) and Lewy-related pathologies were analyzed. Brain infarcts were cate-
gorized by size (<2 mm, 2–15 mm, >15 mm) and by location. Brain
hemorrhages were classified as microscopic (<2 mm) and macroscopic. Results:
195/300 (65%) were demented. 194/195 (99%) of the demented had at least one
neuropathology. Three independent contributors to dementia were identified:
AD-type tau-pathology (Braak stage V-VI), neocortical Lewy-related pathology,
and cortical anterior 2–15 mm infarcts. These were found in 34%, 21%, and
21% of the demented, respectively, with the multivariate odds ratios (OR) for
dementia 5.5, 4.5, and 3.4. Factor analysis investigating the relationships between
different pathologies identified three separate factors: (1) AD-spectrum, which
included neurofibrillary tau, Ab plaque, and neocortical Lewy-related pathologies
and CAA (2) >2 mm cortical and subcortical infarcts, and (3) <2 mm cortical
microinfarcts and microhemorrhages. Multipathology was common and
increased the risk of dementia significantly. Interpretation: These results indicate
that AD-type neurodegenerative processes play the most prominent role in
twilight cognitive decline. The high prevalence of both neurodegenerative and
vascular pathologies indicates that multiple preventive and therapeutic
approaches are needed to protect the brains of the oldest old.
Introduction
People aged ≥85 years old represent the fastest growing
age group in Western countries, projected to increase 3.45-
fold in the US by 2050 (The U.S. Census Bureau 2012,
http://www.agingstats.gov/Main_Site/Data/2012_Documents/
Population.aspx). Because of the consequences of aging –
such as dementia – these people are likely to need help of
the health and social care services. Care of people with
dementia is a major economic burden in Western soci-
eties. Its total cost in the US was 604 billion US$ in 2010.1
Therefore, prevention of dementia should be one of the
main aims of the health care service.
The most common dementing disorder is Alzheimer’s
disease (AD), with estimated prevalence of 45% among
the US citizens aged ≥85 in 2012.2 Vascular dementia
(VaD) and dementia with Lewy bodies (DLB) were esti-
mated to comprise about one-third of all new dementia
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cases in the US.3 However, various pathologies may coex-
ist in the brains of elderly individuals. For example, two-
thirds of elderly AD patients have concomitant other brain
pathologies such as cerebrovascular disease or Lewy-body-
related4,5,6 potentially resulting in “mixed” dementia.7
Previous neuropathological studies of mixed dementia
have mostly focused on hospital-based series on ≤85 years
old. To develop preventive measures against major com-
ponents of dementia one must determine in which rela-
tion they prevail and coexist in the general old
population, when clinically diagnosed dementia is present
or absent. Recently, community-based studies8,9,10 have
added knowledge on the effect of multiple pathologies on
dementia in the very old. We have addressed this ques-
tion by performing a population-based and prospective
neuropathological study on very elderly subjects (Vantaa
85+ study), to analyze the frequency and co-occurrence of
common old-age-associated neuropathologies and their
impact on the development of clinical dementia.
Materials and Methods
Vantaa 85+ study protocol and participants
Vantaa 85+ Study included all individuals aged ≥85 years
living in the city of Vantaa in Southern Finland on April 1,
1991. The clinical follow-up studies were carried out in
1994, 1996 and 1999 for the survivors. Of the 601 eligible
subjects, 552 participated at least in the first clinical follow-
up study. Postmortem neuropathological examinations were
performed in 304/601 (50.9%). Four were excluded due to
the insufficient clinical data, resulting in 300 subjects com-
prising the autopsied subpopulation of this study (Table S1).
Clinical examination
The diagnosis of dementia followed the criteria of the
Diagnostic and Statistical Manual of Mental Disorders,
3th edition, revised (DSM III-R; American Psychiatric
Association, 1987). The diagnosis was based on the
Mini-Mental State Examination (MMSE), required the
consensus opinion by two neurologists11 and had to be set
earlier than 3 months before death. Median time between
the diagnosis of dementia and death was 16 months, SD
13 months. There were 313 demented subjects, of whom
195 were autopsied. Apolipoprotein E (APOE) genotyping
was carried out as previously described.12
Macroscopic examination of the brain
The brains were fixed for at least 2 weeks in 4% phos-
phate-buffered formaldehyde. After external examination,
the cerebrum, brain stem, and cerebellum were separated
from each other. The cerebrum was cut in 1-cm-thick
coronal and the brain stem and cerebellum in 5-mm-
thick sagittal slices. The presence, location, and number
of macroscopic small (2–15 mm) or large (>15 mm)
infarcts in the cerebral cortex, white matter, basal ganglia
region, cerebellum and brainstem were categorized as
hemispheric and deep subcortical.13
Microscopic analyses
Neurodegenerative lesions: Alzheimer’s disease
and Lewy-related pathologies
The analysis of AD-related pathologies was performed fol-
lowing the original criteria.14,15 Density of the neuritic
senile plaques (CERAD score) in sections stained with
modifed Bielschowsky silver method was scored according
to the Consortium to Establish Registry for Alzheimer’s
Disease (CERAD) criteria.14 Neuritic senile plaques were
detected as silver-positive neocortical aggregations which
may or may not have surrounded an intensively staining
central core, and also included at least one intensively
staining elongated structure orientating from the periphery
toward the centre of the aggregate. Braak stages for the
AD-related neurofibrillary tangles were defined using
Gallyas silver-stained 80-lm-thick sections cut from poly-
ethylene glycol-embedded samples from the entorhinal
cortex at the level of the mammillary bodies, from the hip-
pocampus at the level of the lateral geniculate body, and
from the occipital lobe, so that the striate area, parastri-
atale field, and peristriate region were all represented in
the sample.15 The quantities of the plaques and tangles
were counted in four specimens (middle frontal, superior
temporal, and middle temporal gyri and inferior parietal
lobule). The amount of b-amyloid protein was analyzed
by quantifying the fraction of the cortical specimens cov-
ered by methenamine silver-stained plaques. Contiguous
cortical microscopical fields were examined, extending
from the pial surface to the white matter, at a magnifica-
tion of 100 with a square microscopical graticule.17 The
tangles were counted in the modifed Bielschowsky silver-
stained sections in contiguous cortical microscopical fields,
extending from the pial surface to the white matter, at a
magnification of 200 with a square microscopical counting
frame, 0.55 mm in width, along a line perpendicular to
the pial surface.17 The Lewy-related pathology was assessed
according to the consensus criteria18 using histological
staining methods and IHC against a-synuclein clone 42.19
Vascular lesions: cerebral amyloid angiopathy,
microscopic ischemic lesions, and hemorrhages
The diagnosis of cerebral amyloid angiopathy (CAA, the
deposition of amyloid b (Ab) -derived amyloid in the
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subarachnoid and intracortical small and middle-sized
blood vessels) in six brain regions (frontal, parietal, tem-
poral and occipital lobes, hippocampus, and cerebellum)
was based on Congo red, confirmed using IHC against
Ab peptide clone 4G8.20 The severity of CAA was assessed
by counting the percentage of the Congo Red-positive
and Ab immune reactive small and middle-sized vessel
profiles of all vessel profiles seen in samples obtained
from each region. The counts were combined to create
the median value for all six regions. The values higher
than the upper quartile (Q3) value (5.3% for all six brain
regions and 6% for the frontal lobe) were defined as sev-
ere forms of CAA.
The presence and count of old cortical microinfarcts
and microhemorrhages were investigated in six brain
regions (above). The microinfarcts, defined as focal
lesions ≤2 mm and invisible to the naked eye showing
neuronal loss, glia cell, and macrophage reaction and/or
cystic tissue necrosis, were evaluated in the Hematoxylin–
Eosin stained 6-lm-thick tissue sections. The presence of
iron containing macrophages, reflecting the microhemor-
rhage, was verified using the Prussian blue stain. These
microscopic diagnoses were set by at least two patholo-
gists (AP, MT, or MM).
Statistical analyses
Statistical analyses were performed using IBM SPSS Statis-
tics version 20 (IBM, New York, USA) software. Logistic
regression was used to study the associations between dif-
ferent neuropathologies and dementia (Tables 1,2). Recip-
rocal correlations between the neuropathological and
genetic variables were analyzed using Spearman bivariate
correlation analysis (Table 3). The variance in eight quan-
titative variables was analyzed using factor analysis with
the principal component analysis and rotation method
(Fig. 1, Table S2). Statistical analyses were performed by
two investigators (MT, I-LN).
Approval for the study
The Vantaa 85+ study was approved by the Ethics
Committee of the Health Centre of the City of Vantaa.
The Finnish Health and Social Ministry approved the
use of the health and social work records and death
certificates. The National Authority for Medicolegal
Affairs (VALVIRA) has approved the collection of the
tissue samples at autopsy and their use for research.
Blood samples were collected after having obtained an
informed consent from the subjects or their relatives.
The consent for autopsy was obtained from the nearest
relative.
Results
Prevalence of different types of
neuropathologies in the population
194/195 of the demented and 105/105 of the nonde-
mented subjects had at least one type of neuropathology
(any severity, any location) of the five categories shown
in Table 1: (1) AD-type (2) Lewy-related, (3) brain
infarct, (4) CAA, and (5) brain hemorrhage. Thus, with
the exception for one demented subject, all 300 subjects
had at least one type of neuropathology. The prevalence
of each neuropathology type/subtype in the demented
and nondemented subjects is presented in Table 1.
Neuropathological variables and dementia
Dementia was diagnosed in 195/300 (65%). The associa-
tions between individual neuropathological categories and
dementia were first tested with univariate analysis
(Table 1). Among the evaluated parenchymal AD-type
pathologies, Braak stage V–VI had the strongest association
with dementia (OR: 10.76, 95% CI: 4.23–27.35). Lewy-
related pathology, when spread to the neocortex had also a
strong and significant association with dementia (OR: 4.78;
95% CI: 1.94–11.78), whereas Lewy-related pathology in
the brainstem and limbic regions was not associated with
dementia. Of the brain infarcts, 2–15 mm cortical infarcts
(highest OR: 2.84, 95%, CI: 1.32–6.10 for cortical infarcts
in the estimated territory of the anterior circulation) or
thalamic infarcts (OR: 2.45, 95% CI: 1.03–5.79) associated
with dementia. CAA in any brain region was associated
with dementia (OR: 2.27, 95% CI: 1.37–3.77) but the asso-
ciation was strongest for severe CAA in the frontal lobe
(OR: 3.67, 95% CI: 1.84–7.08). CERAD scores C and B
were also associated with dementia in the univariate analy-
sis (OR: 7.83 (2-75-22.34) and 2.78 (1.56–4.96).
In order to identify the independent contributions of
each pathology to the prediction of dementia, we applied
a multivariate analysis (Table 1). In the multivariate
model the variable with the strongest association with
dementia from each pathology category was selected as a
covariate and these were tested together in the same anal-
ysis. From the AD-type pathology group, however, we
included both Braak stage and CERAD score, both as cat-
egorical variables (Table 1), and in total there were five
strong pathologies that were analyzed in multivariate
analysis, in addition to gender, age at death, and the car-
riership of the APOE e4. Three of these five pathological
variables associated independently with dementia in the
multivariate analysis (Table 1): (1) Braak stage V–VI, (2)
diffuse neocortical type of Lewy-related pathology, and
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(3) cortical 2–15 mm infarcts in the anterior parts of the
brains. Braak stage V–VI was the most significant risk fac-
tor for dementia both in the univariate and multivariate
analyses (Table 1). Severe frontal CAA showed a
borderline association with dementia in the multivariate
analysis (P = 0.057), whereas CERAD score and APOE
e4-carrier status were not independently associated with
dementia in the multivariate model (P < 0.1).
Table 1. Frequency of various neuropathologies and association of such pathologies with dementia in the autopsied subpopulation in the Vantaa
85 + study.
Autopsied population
N = 300 Dementia
Neuropathology present
Demented
N = 195
Nondemented
N = 105
OR (95% CI) P -value1
Univariate
OR (95% CI) P -value1
Multivariate2
Alzheimer type
Braak stage
Braak stage3 0–II 45 (23.1) 44 (41.9) Reference
Braak stage III–IV 84 (43.1) 55 (52.4) 1.493 (0.873–2.555) 0.143 1.161 (0.590–2.284) 0.666
Braak stage V–VI 66 (33.8) 6 (5.7) 10.756 (4.230–27.351) <0.001 5.554 (1.546–19.958) 0.009
CERAD score
CERAD score4 0 33 (17.0) 38 (36.2) Reference
CERAD score A 17 (8.7) 16 (15.2) 1.223 (0.535–2.797) 0.633 1.545 (0.570–4.189) 0.393
CERAD score B 111 (56.9) 46 (43.8) 2.779 (1.557–4.959) 0.001 1.744 (0.821–3.705) 0.148
CERAD score C 34 (17.4) 5 (4.8) 7.830 (2.745–22.337) <0.001 2.366 (0.512–10.928) 0.270
Lewy-body-related: DLB category5
Lewy bodies absent (brainstem) 120 (61.6) 84 (80.0) Reference NI
Lewy bodies present
Brainstem predominant/limbic type 34 (17.4) 15 (14.3) NS NI
Diffuse neocortical type 41 (21.0) 6 (5.7) 4.78 (1.94–11.78) 0.001 4.486 (1.578–12.752) 0.005
Infarct6
Absent 71 (36.4) 49 (46.7) Reference NI
Present 124 (63.6) 56 (53.3) NS NI
Superficial total 85 (43.6) 32 (30.5) 1.76 (1.07–2.91) 0.027 NI
Superficial > 15 mm 40 (20.5) 15 (14.3) NS NI
Superficial 2–15 mm 65 (33.3) 22 (21.0) 1.87 (1.08–3.29) 0.025 NI
Superficial cortical 2–15 mm 45 (23.1) 11 (10.5) 2.56 (1.26–5.2) 0.009 NI
Superficial cortical anterior 2–15 mm 41 (21.0) 9 (8.6) 2.84 (1.32–6.10) 0.008 3.400 (1.268–9.12) 0.015
Superficial cortical posterior 2–15 mm 31 (15.9) 8 (7.6) 2.29 (1.01–5.19) 0.047 NI
Deep subcortical total 76 (39.0) 32 (30.5) NS NI
Deep subcortical >15 mm 10 (5.1) 6 (5.7) NS
Deep subcortical 2–15 mm 72 (36.9) 29 (27.6) NS NI
Thalamic 2–15 mm 29 (14.9) 7 (6.7) 2.45 (1.03–5.79) 0.042 NI
Microscopic cortical <2 mm 34 (17.4) 16 (15.2) NS NI
Cerebral amyloid angiopathy (CAA)
Absent in all 6 brain regions6 47 (24.1) 44 (41.9) Reference NI
Present
In any 6 7 brain regions 148 (75.9) 61 (58.1) 2.27 (1.37–3.77) 0.002 NI
In the frontal lobe 124 (63.6) 45 (42.9) 2.33 (1.43–3.78) 0.001 NI
Severe CAA
Severe CAA in 6 brain regions8 60 (30.8) 15 (14.3) 2.67 (1.43–4.98) 0.002 NI
Severe CAA in the frontal lobe9 62 (31.8) 12 (11.4) 3.61 (1.84–7.08) <0.001 2.614 (0.973–7.024) 0.057
Cerebral hemorrhage
Absent 78 (40.0) 34 (32.4) Reference
Present 117 (60.0) 71 (67.7) NS NI
Macroscopic 4 (2.1) 3 (2.9) NS NI
Cortical microscopic 115 (59) 70 (66.7) NS NI
Cortical microscopic with >5 siderophages 10 (5.1) 6 (5.7) NS NI
(Continued)
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Prevalence of multipathology
We next analyzed the co-occurrence of different types of
neuropathologies. We included in the analysis the three
independent neuropathological contributors of dementia
(Braak stage V–VI, diffuse neocortical type of Lewy-
related pathology, and anterior cortical 2–15 mm
infarcts). In addition, as a representative of the Ab
pathology, severe frontal CAA was included, because the
association between dementia and severe frontal CAA in
the multivariate analysis was nearly significant, whereas
the association between CERAD score and dementia was
insignificant (Table 1). One-third of the demented had at
least two and two-thirds had at least one of these most
significant variables (Table 2). The risk for dementia of
subjects with two or more of these four pathologies was
almost two times higher than in those with only one of
these pathologies (OR: 10.07, 95% CI: 3.57–28.28 vs. 5.41
95% CI: 2.75–10.62). On the other hand, one-third of the
demented subjects did not have any of these pathologies.
The distribution of these pathologies at an individual level
is shown in Figure 2, highlighting that the distribution of
these neuropathologies is random. The combination of
tau- and neocortical Lewy-body-related pathologies pro-
duced the highest risk (Table S3).
Relationships between the various
neuropathologies
Correlation analysis (Table 3) revealed correlations
between the AD-type pathologies, neocortical Lewy-
related pathology and CAA. Different types of brain
Table 1. Continued.
Autopsied population
N = 300 Dementia
Neuropathology present
Demented
N = 195
Nondemented
N = 105
OR (95% CI) P -value1
Univariate
OR (95% CI) P -value1
Multivariate2
Covariates
Age at death, mean (SD) 92.5 (3.7) 92.2 (3.8) NS NS
Male gender 30 (15.4) 22 (21.0) NS NS
Apolipoprotein E e4 –carrier 72 (39.6) 16 (16.7) 3.27, 1.77–6.04 (<0.001) 1.096 (0.462–2.597) 0.836
OR, Odd’s ratio; CI, confidence interval; NI, not included; NS, nonsignificant; DLB, dementia with Lewy bodies.
1Bivariate logistic regression analysis.
2Within each neuropathology category (Alzheimer, Lewy body, etc.) only the variable with strongest association with dementia was selected in
the multivariate model. However, for AD-type pathology, both Braak stage and CERAD score were included and analyzed as categorized variables.
Other included variables were diffuse neocortical type of the Lewy body -related pathology, cortical anterior infarcts 2–15 mm, severe CAA in the
frontal lobe10. These selected variables were analyzed together with other covariates (age at death, gender, and the possession of Apolipoprotein
E e4 allele).
3Subjects having neurofibrillary pathology in the neocortex versus subjects with such pathology in hippocampus, entorrhinal cortex, or limbic area
or without such pathology (Braak15).
4Subjects with frequent plaques in the neocortex versus subjects with no to moderate plaques (Mirra et al.,14).
5McKeith et al.,18
6After: Troncoso et al.13 We used the designation “superficial” for cortical and superficial subcortical lesions and the designation “deep subcorti-
cal” for lesions situated in the basal ganglia, brainstem, cerebellum, and capsula interna.
7Frontal, temporal, parietal and occipital lobe, hippocampus, cerebellum.
8Congo red positivity and Ab immunoreactivity detected in 5.3% (Q3 value) of all vessel profiles in the 6six brain regions (Tanskanen et al.,20).
9Congo red positivity and Ab immunoreactivity detected in >6% (Q3 value) of the vessel profiles in the frontal lobe (Tanskanen et al.,20).
Table 2. The effect of combined counts of four most significant
neuropathologies on dementia.
Autopsied population N = 300
Number of
pathologies2
Demented
N = 195
Nondemented
N = 105 OR (95% CI)3,4
0 65 (33.3) 80 (76.2) Reference
1 69 (35.4) 18 (18.4) 5.41 (2.75–10.62)1
2 44 (22.6) 6 (7.0) 9.91 (3.23–30.39)1
3 15 (7.7) 1 (1.2) 10.84 (1.26–93.03)1
4 2 (1.0) 0 (0.0) n.a.
2–4 61 (31.3) 7 (8.0) 10.07 (3.57–28.28)1
OR, Odd’s ratio; CI, confidence interval; n.a., not applicable.
1Significant.
2Pathologies associating significantly with dementia (Braak stages
V–VI, the presence of diffuse neocortical type of Lewy-body-related
pathology, frontal CAA > Q3 value (6%), and macroscopic infarcts 2–
15 mm in the cortex supplied from anterior and middle cerebral arter-
ies, see: Table 1).
3Bivariate logistic regression analysis.
4Adjusted for age at death, gender and the possession of Apolipopro-
tein E e4 allele.
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infarcts correlated with each other and APOE e4 corre-
lated with AD-type parenchymal pathology, CAA and
microscopic (<2 mm) cortical infarcts. To investigate the
relationships of different pathologies further we used fac-
tor analysis. This analysis identified three separate factors:
(1) AD-spectrum, which included neurofibrillary tau
pathology, Ab plaque pathology, CAA, and neocortical
Lewy-related pathology, (2) >2 mm cortical and subcorti-
cal infarcts, and (3) <2 mm cortical microinfarcts and
microhemorrhages (Fig. 1, Table S2).
Discussion
We have performed a study on the spectrum of various
neuropathologies underlying dementia in a population-
based study on subjects aged ≥85 years. Our major find-
ings were: (1) the prevalence of any age-associated brain
pathology was extremely high (99.7%), (2) neurofibrillary
AD-type pathology (Braak stage V–VI) was the strongest
independent neuropathological correlate of dementia,
although two other pathologies (neocortical type of Lewy-
related pathology, and 2–15 mm cortical infarcts espe-
cially in the territory of the anterior circulation) also
associated independently with dementia, (3) the different
types of neuropathologies formed up into three separate,
frequency-based “clusters”. (4) multipathology is common
in the very elderly demented individuals and increases the
risk of dementia significantly.
Neuropathological and clinical diagnoses
Autopsy with neuropathological examination is often
needed to determine the background of dementia, in
addition to the clinical and radiological examinations.
Today, neuropathological examination is a prerequisite
for the definite diagnosis of AD.21 However, in the very
elderly, the differential diagnostics of dementia syndromes
may be challenging.17 Although the contemporary neu-
ropathological diagnosis of AD notifies some other
pathologies than the AD-related, such as DLB with con-
sensus neuropathological criteria18 there are conditions
such as VaD that lack such criteria. Therefore, we used
the clinical dementia diagnosis as a starting point, and
tested the presence versus not presence of clinical demen-
tia against the panel of neuropathological components.
The criteria for the clinical diagnosis of dementia can be
considered strict enough to reliably differentiate between
the demented and nondemented. Our neuropathological
Table 3. Results of correlation analyses between the various quantitative neuropathological variables and the possession of apolipoprotein E e4
allele in the whole autopsied subpopulation (N = 300) of the Vantaa 85 + Study.
AD type
Lewy rel
Infarct (N)
CAA3 Hem (N) APOE
Tangle4 Plaque5 Neocortical6 Hemisph7 Deep sc8
Microsc.
<2 mm9 6 regions10
Microsc.
cortical e4-carrier
AD type Tangle4 1.000 0.5912 0.1281 0.028 0.008 0.1211 0.4602 0.030 0.4272
Plaque5 0.5912 1.000 0.1241 0.066 0.022 0.059 0.4872 0.004 0.4602
Lewy rel Neocortical6 0.1281 0.1241 1.000 0.026 0.025 0.003 0.052 0.043 0.102
Infarct (N) Hemisph7 0.028 0.066 0.026 1.000 0.2142 0.1411 0.045 0.014 0.103
Deep sc8 0.008 0.022 0.025 0.2142 1.000 0.010 0.060 0.005 0.038
Microsc.
<2 mm9
0.1211 0.059 0.003 0.1411 0.010 1.000 0.1301 0.102 0.1642
CAA3 6 regions10 0.4602 0.4872 0.052 0.045 0.060 0.1301 1.000 0.016 0.4812
Hem (N) Microsc. cortical 0.030 0.004 0.043 0.014 0.005 0.102 0.016 1.000 0.022
APOE e4carrier 0.4272 0.4602 0.102 0.103 0.038 0.1642 0.4812 0.022 1.000
The counts represent correlation coefficients (Spearman’s q).
AD, Alzheimer’s disease; Lewy rel, Lewy-related pathology; CAA, cerebral amyloid angiopathy; Hem, hemorrhage; APOE, Apolipoprotein E; Tan-
gle, neurofibrillary tangle, Plaque, methenamine-silver-positive plaque (any type); Hemisph, hemispheric; Deep sc, deep subcortical; Microsc, micro-
scopic.
1Significant at the 0.005 level.
2Significant at the 0.001 level.
3Percentage of the amyloid laden blood vessels of all vessels (Tanskanen et al., NAN 2012; 38: 329-36).
4Average number of neurofibrillary tangles in the four cortical regions (frontal, temporal, parietal, occipital).
5Percentage of neocortex covered by methenamine silver-positive plaques (frontal, temporal, parietal, occipital, Polvikoski et al.,16).
6The presence or absence of neocortical Lewy bodies in the temporal, frontal and parietal lobes and cingulate gyrus (McKeith et al.,18).
7Macroscopic infarcts in the cerebral cortex and superficial subcortical white matter (Troncoso et al.,13).
8Macroscopic infarcts in the basal ganglia, brainstem, and cerebellum (Troncoso et al.,13).
9Microscopic cortical infarcts <2 mm.
10Frontal, temporal, parietal, occipital lobe, hippocampus, cerebellum.
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analyzes followed the traditional neuropathological
parameters for AD14,16 and LBD. These criteria have
recently been refined and adjusted for the needs of clini-
cal diagnostics, for example, by applying IHC-based
methods but the original methods can still be judged reli-
able indicators of the severity of the pathology.22,23,24 For
the assessment of CAA several methods have been pro-
posed. Here we have preferred the above described, allow-
ing quantitative analyses based on whole tissue sections.20
The neuropathological spectrum of the aged
brain
The extremely high prevalence of any neuropathology
(99.7%) shows that the development of at least some type
of neuropathology during aging seems inevitable. The
extremely high frequency of the AD-related pathologies
(291/300 [97%] with Braak stage >0 or CERAD score>0,
strongly contributed to this count similarly as in another
population-based study (Honolulu Asia Aging Study,
HAAS) on elderly subjects.25 Other population-based
studies had found somewhat lower frequencies of AD-
type pathologies1,13,26–28, probably as those studies
included younger subjects, with lower mean age at death,
as compared to our study (92.4 years for the autopsied
population, Table S1). Indeed, Strotzyk et al. reported
AD in 55/190 of subjects in a community-based series
with mean age at death was 84.4 years.29 Other common
pathologies were CAA (any severity 209/300 [70%]), cor-
tical microhemorrhages (185/300 [62%]), and brain
infarcts (180/300 [60%]). The significance of CAA in
dementia has been somewhat unclear. Previous popula-
tion-based studies1,30,31 have demonstrated higher
prevalence of CAA in the demented as compared with the
nondemented, referring to an impact for CAA for the
development of dementia. However, only one population-
based study has demonstrated an independent association
between CAA and dementia.26 This discrepancy28 may
reflect the effect of variability in the selection of variables
in the multivariate analyses. Some brain lesions, such as
cortical microhemorrhages, although associated with age32
did not associate with dementia. There are only few histo-
logical studies on MH and dementia. One previous
study33 found microhemorrhages to be frequent in AD
brains in contrast to us (Table 3). Hemorrhage, also
microhemorrhage, can be a manifestation of CAA34 but
here we did not find a statistical association between the
presence of microhemorrhage and CAA (Table 3). One
reason for these discrepancies may be that the presence of
microhemorrhage was analyzed here in the cortical
regions only.
The significant neuropathologies
In this study, the AD-related tau-pathology (Braak stages
V–VI, Table 1) was the strongest single contributor to
dementia, but the impact of the neocortical Lewy-related
pathology was also strong. These findings are consistent
with previous longitudinal studies investigating neu-
ropathological correlates of dementia.13,26,27,28,29,35,36,37
Several studies also have demonstrated a strong associa-
tion between high CERAD score and dementia, but the
results in the multivariate analyses have varied. Similar to
our study, the association was lost in one study27, in con-
trast to another26 in which the strong association pre-
vailed in the multivariate analysis. These discrepancies
may reflect the differences in the variables selected in the
multivariate analyses.
We confirmed the previous findings on the indepen-
dent association between dementia and cerebral small
macroscopic infarcts (2–15 mm)13,36, emphasizing the
role of vascular backgrounds in dementia in the very
elderly. Indeed, not only cerebral infarcts but even
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Figure 1. The variance in eight quantitative variables, as analyzed
using factor analysis: The variables (components) investigated
consisted of counts of neurofibrillary tangles (tangles), percentage of
cortical thickness covered by methenamine silver-positive senile
plaques (plaques), hemispheric and deep macroscopic infarcts, cortical
micro infarcts <2 mm (MI), cortical microhemorrhages (MH), and the
severity of cerebral amyloid angiopathy (CAA) in six brain regions, and
the presence/absence of neocortical Lewy bodies, as illustrated in a
three-dimensional form. Three factors explaining the variability
between the eight components investigated were extracted (Table 2)
showing that the cluster of four variables (Factor 1, red color),
consisted of tangles, plaques, CAA and the neocortical type of Lewy-
body-related pathology, explained the majority of the variability
between the variables.
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atherosclerosis of the cerebral large and small vessels have
recently shown to increase the risk of AD-type demen-
tia.38 However, the association between dementia and the
presence of 2–15 mm cortical infarcts in the anterior
parts of the brain was even stronger (OR: 2.84, 95% CI:
1.32–6.10), and represented an independent determinant
of dementia, thus referring to the role of lesion localiza-
tion in the clinical outcome, independent from the back-
ground (an obstruction/decreased blood flow in either the
local small blood vessels or larger arteries). The associa-
tion between cerebral microscopic infarcts and dementia,
found in several previous studies1,13,27,36 was not con-
firmed here, most probably as we have not analyzed white
matter lesion but cortical microscopic infarcts only.
Although deep infarcts as a group did not associate with
dementia, similar to another longitudinal study13, we
showed the significance of infarcts in the thalamic region
in cognitive impairment (Table 1).
The network of various neuropathologies
Factor analysis has mainly been applied in the social
sciences, for instance, in the opinion polls. It measures the
conceptual distance between different quantitative variables
relative to each other. Here we applied the method for the
first time on a neuropathological study, to identify the set-
tling of the quantitative variables in relation to the others
to form variable “clusters”. The resulting perspective
(Fig. 1, Table S3) recapitulated the results of the correla-
tion analysis (Table 3). The AD-type pathology, CAA, and
Lewy-related pathologies were separated into their own
“cluster” (Factor 1, “AD-spectrum”). The placing of the
Lewy-related pathology in the “AD-spectrum” is not unex-
pected, as the Lewy-related pathology – when present –
tends to coexist with AD pathology.39 This also explains
the high association between the combinations of these
pathologies and dementia. The natural background for the
second “cluster” (Factor 2, the macroscopic >2 mm
infarcts) is arteriosclerosis/thrombosis of the arterioles and
larger arteries. The third “cluster” (Factor 3) consisted of
cortical microinfarcts and microhemorrhages. Although
both components of this “cluster” potentially represent a
type of capillary injury neither was associated with demen-
tia. Thus, apart from CAA, the various vascular pathologies
in this study did not seem to be linked with the AD- or
Lewy-related pathologies, suggesting that these vascular
and primary neurodegenerative pathologies mainly are
independent from each other, as suggested previously.25
Multipathology
We show the extent (Tables 1,2) and spectrum (Fig. 1,2
and Table S2, S3) of the concomitant pathologies in the
brains of the oldest old, demonstrating the high fre-
quency of multiple pathologies, as has been reported
before.37 The increase in the number of pathologies
increased the OR for dementia (Table 2, Figure 2), simi-
larly to other recent community-based studies.8,9,10 It is
of interest that the effect on multipathology on dementia
was similar in spite of differences in the pathologies
included in the “mixed” pathology group in the different
studies. For example, in the study of Kawas et. al.9, the
subjects were categorized in four different groups, based
on the presence and severity of AD pathology and the
presence of other type of pathologies, whereas another
study10 focused on the presence of AD and TDP-43
pathologies. These results imply that the association
between multipathology and dementia is not restricted to
specific neuropathologies or their combinations but sev-
eral different combinations of several different neu-
ropathologies may increase the risk of dementia. Second,
the clinical diagnosis and especially the determination of
the type of dementia in the very old may be challeng-
ing,40 as many patients fulfill more than one diagnostic
criterion and more than one pathophysiology. Third, it
is possible that the co-occurrence of multiple pathologi-
cal processes in the brain and their additive effect in the
risk of dementia may also have a deteriorating effect on
the reliability of short term drug trials lacking neu-
ropathological confirmation of the diagnoses.37 On the
other hand, probably as a result of this multipathology,
many modifiable risk factors for dementia have been
identified41 and several of them are (1) shared with
atherosclerotic cerebrovascular disease and (2) amenable
to simple preventive measures of, for example, lifestyle
and nutrition.
Even though we found that two-thirds of the demen-
ted subjects had at least one of the four pathologies that
associated independently or nearly independently with
dementia (Braak stage V–VI, diffuse neocortical type of
Lewy-related pathology, anterior cortical 2–15 mm
infarcts and frontal severe CAA), it is noteworthy that
one-third of the demented did not have any of these
pathologies. On the other hand, 99% of the demented
had at least one neuropathology analyzed here, of which
some, for example, the presence of any 2–15 mm corti-
cal infarcts or CERAD score C may explain dementia in
these individuals. It is also of note that our study lacked
data on some important dementia-associated neu-
ropathologies, for example, hippocampal sclerosis42 and
the other TDP-43-related pathologies as well as primary
age-related tauopathy (PART)43, the analysis of which
are not completed yet in our study material. Further
studies, including these and other, for example, vascular
neuropathologies may further specify the neuropatholog-
ical backgrounds of dementia in the very elderly.
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Figure 2. Distribution of four dementia-associated pathologies in demented and nondemented: Distribution and co-occurrence of the three
neuropathologies which associate independently with dementia: Braak stages V-VI (blue color), neocortical Lewy-related pathology (green color),
and the presence of 2–15 mm infarcts in the anterior cortical regions (yellow color), and severe cerebral amyloid angiopathy (CAA) in the frontal
lobe (red color, borderline association). Individual level presentation, one bar represents one subject.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Table S1. Demonstrates the demographic features of the
whole Vantaa 85 + population compared with the neu-
ropathologically examined (autopsied) subpopulation.
Table S2. Demonstrates the results of factor analysis
investigating the variance in eight quantitative variables:
the neurofibrillary tangles, senile plaques, Lewy-body-
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related pathology, infarcts (macroscopic hemispheric and
deep subcortical, microscopic, MI), cerebral amyloid
angiopathy (CAA), and microscopic hemorrhages (MH).
Table S3. Shows the distribution of combinations of the
four pathologies which showed the strongest association
with dementia (Braak stages V–VI, presence of neocortical
Lewy bodies, presence of cortical infarcts 2–15 mm in the
anterior parts of the brains and presence of severe CAA
in the frontal lobe) in the demented and nondemented
subjects in the Vantaa 85 + Study population.
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